A carregar...
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
Obinutuzumab (GA101) is a type II, glycoengineered anti-CD20 monoclonal antibody for the treatment of hematologic malignancies. Obinutuzumab has mechanisms of action that are distinct from those of rituximab, potentially translating into improved clinical efficacy. We present the pharmacokinetic and...
Na minha lista:
| Publicado no: | Haematologica |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ferrata Storti Foundation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4938339/ https://ncbi.nlm.nih.gov/pubmed/26659915 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.133421 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|